Certara had its Relative Strength (RS) Rating upgraded from 69 to 75 Friday — a welcome improvement, but still below the 80 or better score you prefer to see.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they launch their largest price moves. See if Certara can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to offer and clear a proper buy point.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 18%, compared to -42% in the prior report. Revenue increased from 3% to 11%. Keep an eye out for the company's next round of numbers on or around Feb. 26.
Certara holds the No. 6 rank among its peers in the Computer Software-Medical industry group. Doximity, Waystar Holding and Veeva Systems Cl A are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
